• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    8/11/25 4:03:46 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO SECTION 13A-16 OR 15D-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2025 

     

    Commission File Number: 001-41316

     

     

     

    Alpha Tau Medical Ltd.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Kiryat HaMada St. 5

    Jerusalem, Israel 9777605

    +972 (3) 577-4115

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

    CONTENTS

     

    The following documents are attached hereto:

     

    ●Exhibit 99.1. Interim Consolidated Financial Statements as of June 30, 2025.

     

    ●Exhibit 99.2. Operating and Financial Review and Prospects in connection the Interim Consolidated Financial Statements for the six months ended June 30, 2025.

     

    ● Exhibit 99.3. Press Release dated August 11, 2025

     

    The Interim Consolidated Financial Statements of Alpha Tau Medical Ltd. as of June 30, 2025 attached as Exhibit 99.1 and the Operating Results and Financial Review in connection with the Interim Consolidated Financial Statements of Alpha Tau Medical Ltd. for the six months ended June 30, 2025 attached as Exhibit 99.2 to this Report on Form 6-K are hereby incorporated by reference into the registrant’s Registration Statements on Form F-3 (File Nos. 333-271073, 333-264306, 333-274457 and 333-288240) and Form S-8 (File Nos. 333-264169, 333-270406, 333-277733 and 333-285745).

     

    1

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    99.1   Interim Consolidated Financial Statements as of June 30, 2025.
         
    99.2   Operating and Financial Review and Prospects in connection the Interim Consolidated Financial Statements for the six months ended June 30, 2025.
         
    99.3   Press Release dated August 11, 2025
         
    101   The following financial information from Alpha Tau Medical Ltd.’s Report on Form 6-K, formatted in XBRL (eXtensible Business Reporting Language): (i) Interim Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024; (ii) Interim Consolidated Statements of Operations for the six months ended June 30, 2025 and 2024; (iii) Interim Consolidated Statements of Changes in Shareholders’ Equity for the six months ended June 30, 2025 and 2024; (iv) Interim Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024; and (v) Notes to the Interim Consolidated Financial Statements.
         
    104   Cover Page Interactive Data File (embedded within the inline XBRL document).

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Alpha Tau Medical Ltd.
         
    Date: August 11, 2025 By: /s/ Uzi Sofer
        Uzi Sofer
        Chief Executive Officer

     

     

    3

     
    Get the next $DRTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Alpha Tau with a new price target

    Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

    12/15/23 8:07:49 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Alpha Tau with a new price target

    H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

    4/24/23 7:44:43 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on Alpha Tau with a new price target

    Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00

    4/14/22 7:17:36 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DRTS
    SEC Filings

    View All

    Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    - FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot studies, positioned for imminent patient treatment initiation during the remainder of 2025 - - Secured $36.9 million through a strategic equity offering at market price from Oramed, while concurrently entering into a strategic IR/PR alliance - - Cash, cash equivalents & deposits balance of $83.3 million provides runway for continued clinical advancement and commercial preparation - JERUSALEM, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Me

    8/11/25 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau to Present at Jefferies Global Healthcare Conference

    JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025. Event:Jefferies Global Healthcare ConferenceFormat:PresentationDate:June 5, 2025Time:1:25 – 1:55PM ETLocation:New York, NY   Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd.Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and

    5/28/25 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

    - Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -       - 75% systemic objective response rate (ORR) and 37.5% complete response rate meaningfully higher thus far than historical Keytruda® monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in head and neck squamous cell carcinoma (HNSCC) - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-l

    5/19/25 4:01:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    8/11/25 4:03:46 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Alpha Tau Medical Ltd.

    EFFECT - Alpha Tau Medical Ltd. (0001871321) (Filer)

    7/3/25 12:15:16 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form F-3 filed by Alpha Tau Medical Ltd.

    F-3 - Alpha Tau Medical Ltd. (0001871321) (Filer)

    6/23/25 4:56:03 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

    JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

    5/12/25 4:01:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

    - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

    3/12/25 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

    JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

    12/17/24 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care